Skip to main content
Springer Nature Link
Log in

The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy

  • Research Article
  • Published:
Tumor Biology

Abstract

Serum marker evaluation is an easily available prognostic indicator that may help clinicians to discriminate patients with an aggressive disease; there are few and small-sized studies exploring the prognostic role of baseline carcinoembryonic antigen (CEA) values and their variations during first-line therapy, and even fewer data are available for carbohydrate antigen 19–9 (CA 19-9). Our aim was to analyze the role of those prognostic markers to exploit them in daily clinical practice. Data of 892 patients with marker determination before and 3 and/or 6 months during therapy were extracted from two institutional databases. Patients were grouped according to single marker variation as always negative (G0), decreasing (G1), stable (G2), or increasing (G3). We evaluated the progression-free survival (PFS) and the overall survival (OS) of all the patents and correlated them with CEA and CA 19-9 values. A concordance between response to therapy and marker decrease was evident in 50.2 % and in 34.4 % of the patients for CEA and CA 19-9. Patients with low CEA or CA 19-9 baseline values had a longer PFS (15.1 vs. 10.5; 13.6 vs. 10.2 months) and OS (32.0 vs. 22.3; 30.5 vs. 20.1 months). The same results of PFS and OS were obtained by analyzing the data of the four different groups. Multivariate analyses confirmed the independent prognostic role of CEA and CA 19-9. Baseline CEA and CA 19-9 levels and their kinetics demonstrated to be independent prognostic factors. CA 19-9 dosage is not recommended; a possible role of CA 19-9 in patients with negative CEA could be worth further evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69.

    Article  PubMed  Google Scholar 

  2. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Investig. 2005;23(4):338–51.

    Article  Google Scholar 

  3. Al-Sarraf M, Baker L, Talley RW, et al. The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer. 1979;44(4):1222–55.

    Article  CAS  PubMed  Google Scholar 

  4. De Gramont A, Krulic M, Kadi J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1988;24(9):1499–503.

    Article  PubMed  Google Scholar 

  5. Barone C, Astone A, Cassano A, et al. Advanced colon cancer: staging and prognosis by CEA test. Oncology. 1990;47(2):128–32.

    Article  CAS  PubMed  Google Scholar 

  6. Michl M, Koch J, Laubender RP, et al. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy. Tumour Biol. 2014 Jul 15.

  7. Galli C, Basso D, Plebani M. CA 19-9: handle with care. Clin Chem Lab Med. 2013;51(7):1369–83.

    Article  CAS  PubMed  Google Scholar 

  8. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: a project of the programme on clinical oncology of the international union against cancer, Geneva, Switzerland. Cancer. 1977;39:1289–94.

    Article  CAS  PubMed  Google Scholar 

  9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  Google Scholar 

  10. Boeck S, Haas M, Laubender RP, et al. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res. 2010;16(3):986–94.

    Article  CAS  PubMed  Google Scholar 

  11. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol. 2013;85(1):45–81.

    Article  PubMed  Google Scholar 

  12. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lochhead P, Imamura Y, Morikawa T, et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 2012;48(18):3405–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2011;35:684–92.

    Article  PubMed  Google Scholar 

  15. Mitsuyama Y, Shiba H, Haruki K, et al. Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis. Oncol Lett. 2012;3(4):767–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–35.

    Article  CAS  PubMed  Google Scholar 

  17. Strimpakos AS, Cunningham D, Mikropoulos C, Petkar I, Barbachano J, Chau I. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol. 2010;21:1013–9.

    Article  CAS  PubMed  Google Scholar 

  18. Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70:255–64.

    Article  CAS  PubMed  Google Scholar 

  19. Charbel H, Al-Kawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep. 2011;13(2):182–7.

    Article  PubMed  Google Scholar 

  20. Jamaludin AZ, Metassan MM, Zainal-Abidin Z, et al. Elevated serum CA 19-9 in association with Hashimoto thyroiditis. Singap Med J. 2010;51(8):143–5.

    Google Scholar 

  21. Bertino G, Ardiri AM, Calvagno GS, et al. In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology. Dig Liver Dis. 2010;42:457–9.

    Article  Google Scholar 

  22. Tampellini M, Berruti A, Bitossi R, et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat. 2006;98(3):241–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SCDU Oncologia, AOU San Luigi Gonzaga, Orbassano, Italy

    M. Tampellini, A. Ottone, C. Baratelli, E. Aroasio & G. V. Scagliotti

  2. SC Oncologia, Ospedale San Giovanni Bosco, Torino, Italy

    I. Alabiso

  3. SCDU Oncologia, AOU Maggiore della Carità, Novara, Italy

    L. Forti

  4. Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica, Università di Brescia, Oncologia Medica. Azienda Ospedaliera Spedali Civili, Brescia, Italy

    A. Berruti

Authors
  1. M. Tampellini
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. A. Ottone
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. I. Alabiso
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. C. Baratelli
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. L. Forti
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. A. Berruti
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. E. Aroasio
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. G. V. Scagliotti
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to C. Baratelli.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tampellini, M., Ottone, A., Alabiso, I. et al. The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumor Biol. 36, 1519–1527 (2015). https://doi.org/10.1007/s13277-014-2693-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2693-3

Keywords